We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
FORMA Therapeutics Announces Oncology Collaboration with Novartis
News

FORMA Therapeutics Announces Oncology Collaboration with Novartis

FORMA Therapeutics Announces Oncology Collaboration with Novartis
News

FORMA Therapeutics Announces Oncology Collaboration with Novartis

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "FORMA Therapeutics Announces Oncology Collaboration with Novartis"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

FORMA Therapeutics announced that it has entered into a collaboration agreement with Novartis. Under the terms of the agreement, FORMA will utilize its cell-based screening platform to discover inhibitors for undisclosed protein-protein interaction targets in the field of oncology. Financial terms of the collaboration were not disclosed.

“FORMA is pleased to expand its relationship with Novartis beyond our existing agreement with the Novartis Option Fund,” said Steven Tregay, CEO of FORMA. “This collaboration provides additional validation of our fully integrated drug discovery technologies, including our transformative biology and chemistry platforms, which we will use to unlock the elusive protein-protein interaction target class that is so important to oncology drug discovery.”
Advertisement